Is VXF a Good ETF to Buy?
Vanguard’s Extended Market ETF (VXF) is a broad fund made…
Sell
12
ALLK Quote, Financials, Valuation and Earnings
Last price:
$0.26
Seasonality move
:
-9.81%
Day range:
$0.26 - $0.27
52-week range:
$0.23 - $1.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.32x
Volume:
903.5K
Avg. volume:
4M
1-year change:
-81.15%
Market cap:
$23.6M
Revenue:
--
EPS (TTM):
-$2.04
Analysts' Opinion
-
Consensus RatingAllakos has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $0.35, Allakos has an estimated upside of 32.63% from its current price of $0.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $0.30 representing 100% downside risk from its current price of $0.26.
Fair Value
-
According to the consensus of 7 analysts, Allakos has 32.63% upside to fair value with a price target of $0.35 per share.
ALLK vs. S&P 500
-
Over the past 5 trading days, Allakos has underperformed the S&P 500 by -4.36% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Allakos does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Allakos has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Allakos reported revenues of --.
Earnings Growth
-
Allakos has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Allakos reported earnings per share of -$0.21.
Enterprise value:
-69.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.66x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$372.3M | -$177.3M | -$159.1M | -$48.2M | -$19.8M | |
| EBITDA | -$365.6M | -$171.2M | -$154.7M | -$46.7M | -$18.9M | |
| Diluted EPS | -$6.76 | -$1.92 | -$2.04 | -$0.52 | -$0.21 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $424.8M | $531.5M | $339.2M | $218.3M | $97.2M | |
| Total Assets | $440.5M | $621.1M | $418.6M | $283.5M | $124.4M | |
| Current Liabilities | $18.9M | $40.6M | $27.6M | $23.5M | $16M | |
| Total Liabilities | $26.7M | $96.5M | $74.4M | $62.5M | $51.7M | |
| Total Equity | $413.8M | $524.6M | $344.2M | $221M | $72.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$298.6M | -$139M | -$105.4M | -$29.5M | -$31.7M | |
| Cash From Investing | $86.1M | $1.5M | $45.2M | $31.5M | $15.6M | |
| Cash From Financing | $142.6M | $2.7M | $177K | $1.1M | $45K | |
| Free Cash Flow | -$322M | -$139.9M | -$105.5M | -$29.6M | -$31.7M | |
ALLK
Sector
Market Cap
$23.6M
$38.4M
Price % of 52-Week High
16.97%
44.83%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.67%
1-Year Price Total Return
-81.15%
-40.84%
Beta (5-Year)
0.719
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.28
200-day SMA
Sell
Level
$0.87
Bollinger Bands (100)
Sell
Level
0.46 - 1.26
Chaikin Money Flow
Sell
Level
-142M
20-day SMA
Sell
Level
$0.28
Relative Strength Index (RSI14)
Sell
Level
32.26
ADX Line
Sell
Level
32.2
Williams %R
Neutral
Level
-75.43
50-day SMA
Sell
Level
$0.67
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Buy
Level
40
On Balance Volume
Sell
Level
-8.9M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Stock Forecast FAQ
In the current month, ALLK has received 0 Buy ratings 7 Hold ratings, and 0 Sell ratings. The ALLK average analyst price target in the past 3 months is $0.35.
-
Where Will Allakos Stock Be In 1 Year?
According to analysts, the consensus estimate is that Allakos share price will rise to $0.35 per share over the next 12 months.
-
What Do Analysts Say About Allakos?
Analysts are divided on their view about Allakos share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Allakos is a Sell and believe this share price will drop from its current level to $0.30.
-
What Is Allakos's Price Target?
The price target for Allakos over the next 1-year time period is forecast to be $0.35 according to 7 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is ALLK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Allakos is a Hold. 7 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of ALLK?
You can purchase shares of Allakos via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Allakos shares.
-
What Is The Allakos Share Price Today?
Allakos was last trading at $0.26 per share. This represents the most recent stock quote for Allakos. Yesterday, Allakos closed at $0.26 per share.
-
How To Buy Allakos Stock Online?
In order to purchase Allakos stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is PM Stock Up So Much?
Shares of cigarette giant Philip Morris (NYSE:PM) have advanced considerably…
Is Nvidia Stock Still Too Expensive or a Smart Buy?
The $2.8 trillion chip juggernaut NVIDIA Corporation (NASDAQ:NVDA) announced Q4…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $3T
P/E Ratio: 34x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
53
SITM alert for Mar 6
SiTime [SITM] is down 2.22% over the past day.
Buy
71
ASTS alert for Mar 6
AST SpaceMobile [ASTS] is down 4.73% over the past day.
Sell
20
MRNA alert for Mar 6
Moderna [MRNA] is down 2.56% over the past day.
